Insmed Statistics
Total Valuation
Insmed has a market cap or net worth of $25.28 billion. The enterprise value is $24.85 billion.
| Market Cap | 25.28B |
| Enterprise Value | 24.85B |
Important Dates
The next estimated earnings date is Thursday, October 29, 2026, before market open.
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Insmed has 218.38 million shares outstanding. The number of shares has increased by 18.73% in one year.
| Current Share Class | 218.38M |
| Shares Outstanding | 218.38M |
| Shares Change (YoY) | +18.73% |
| Shares Change (QoQ) | +0.87% |
| Owned by Insiders (%) | 0.62% |
| Owned by Institutions (%) | 103.76% |
| Float | 216.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 22.24 |
| Forward PS | 10.85 |
| PB Ratio | 33.91 |
| P/TBV Ratio | 46.12 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 21.87 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.72, with a Debt / Equity ratio of 0.98.
| Current Ratio | 3.72 |
| Quick Ratio | 3.14 |
| Debt / Equity | 0.98 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -9.99 |
Financial Efficiency
Return on equity (ROE) is -87.22% and return on invested capital (ROIC) is -29.14%.
| Return on Equity (ROE) | -87.22% |
| Return on Assets (ROA) | -22.17% |
| Return on Invested Capital (ROIC) | -29.14% |
| Return on Capital Employed (ROCE) | -48.84% |
| Weighted Average Cost of Capital (WACC) | 8.74% |
| Revenue Per Employee | $683,675 |
| Profits Per Employee | -$526,028 |
| Employee Count | 1,664 |
| Asset Turnover | 0.50 |
| Inventory Turnover | 1.51 |
Taxes
In the past 12 months, Insmed has paid $6.21 million in taxes.
| Income Tax | 6.21M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -15.54% in the last 52 weeks. The beta is 0.82, so Insmed's price volatility has been lower than the market average.
| Beta (5Y) | 0.82 |
| 52-Week Price Change | -15.54% |
| 50-Day Moving Average | 119.59 |
| 200-Day Moving Average | 134.36 |
| Relative Strength Index (RSI) | 41.15 |
| Average Volume (20 Days) | 2,042,119 |
Short Selling Information
The latest short interest is 10.80 million, so 4.95% of the outstanding shares have been sold short.
| Short Interest | 10.80M |
| Short Previous Month | 11.44M |
| Short % of Shares Out | 4.95% |
| Short % of Float | 4.98% |
| Short Ratio (days to cover) | 5.74 |
Income Statement
In the last 12 months, Insmed had revenue of $1.14 billion and -$875.31 million in losses. Loss per share was -$4.09.
| Revenue | 1.14B |
| Gross Profit | 949.42M |
| Operating Income | -812.65M |
| Pretax Income | -869.11M |
| Net Income | -875.31M |
| EBITDA | -794.96M |
| EBIT | -812.65M |
| Loss Per Share | -$4.09 |
Balance Sheet
The company has $1.16 billion in cash and $739.72 million in debt, with a net cash position of $420.59 million or $1.93 per share.
| Cash & Cash Equivalents | 1.16B |
| Total Debt | 739.72M |
| Net Cash | 420.59M |
| Net Cash Per Share | $1.93 |
| Equity (Book Value) | 757.49M |
| Book Value Per Share | 3.47 |
| Working Capital | 1.20B |
Cash Flow
In the last 12 months, operating cash flow was -$778.92 million and capital expenditures -$28.75 million, giving a free cash flow of -$807.67 million.
| Operating Cash Flow | -778.92M |
| Capital Expenditures | -28.75M |
| Depreciation & Amortization | 17.69M |
| Net Borrowing | -3.15M |
| Free Cash Flow | -807.67M |
| FCF Per Share | -$3.70 |
Margins
Gross margin is 83.46%, with operating and profit margins of -71.43% and -76.94%.
| Gross Margin | 83.46% |
| Operating Margin | -71.43% |
| Pretax Margin | -76.40% |
| Profit Margin | -76.94% |
| EBITDA Margin | -69.88% |
| EBIT Margin | -71.43% |
| FCF Margin | n/a |
Dividends & Yields
Insmed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -18.73% |
| Shareholder Yield | -18.73% |
| Earnings Yield | -3.46% |
| FCF Yield | -3.19% |
Analyst Forecast
The average price target for Insmed is $199.55, which is 72.41% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $199.55 |
| Price Target Difference | 72.41% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 23 |
| Revenue Growth Forecast (3Y) | 85.44% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on March 3, 2011. It was a reverse split with a ratio of 1:10.
| Last Split Date | Mar 3, 2011 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
Insmed has an Altman Z-Score of 9.79 and a Piotroski F-Score of 3.
| Altman Z-Score | 9.79 |
| Piotroski F-Score | 3 |